Local low-dose IL-2 therapy

Willem Den Otter*, Lianne Balemans, Jan J. Battermann, Monique R. Bernsen, Jenny A. Cadee, Zygmunt Dobrowolski, Linda A. Everse, Lucja Fiszer-Maliszewska, Richard Gavhumende, Jan Willem De Groot, Kees De Groot, Wim E. Hennink, F. W.Graham Hill, Ina Jurgenliemp-Schulz, Wim R. Klein, Jan Willem Koten, Riks A. Maas, Peter Steerenberg, Rachel Stewart, Marek Zembala

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

23 Citations (Scopus)

Abstract

Interleukin-2 (IL-2) is a powerful drug for treating cancer. However, it is only powerful if it is properly applied. That is, IL-2 should be applied at the tumor site, because at the transition of normal and malignant tissue are the tumor infiltrating cells. These should be activated by IL-2. Local application implies that IL-2 can be used in relatively low doses. It is becoming clear that even a single injection of IL-2 can cure cancer. IL-2 can also enhance the therapeutic effects of irradiation and Cisplatin. Locally applied IL-2 therapy is virtually non-toxic.

Original languageEnglish
Pages (from-to)1280-1286
Number of pages7
JournalHepato-Gastroenterology
Volume46
Issue numberSUPPL. 1
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Dive into the research topics of 'Local low-dose IL-2 therapy'. Together they form a unique fingerprint.

Cite this